NanoSyrinx Appoints Tom Farrell as CEO, Focusing on Intracellular Medicine.

jueves, 8 de enero de 2026, 3:32 am ET1 min de lectura
ARTV--

NanoSyrinx, a synthetic biology company, has appointed Thomas J. Farrell as CEO and Director. Farrell has over 25 years of biotherapeutics leadership experience, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding. He will lead the company in developing Nanosyringes as a platform for targeted intracellular delivery of biologic therapeutics. Founder Joe Healey will remain involved as a scientific leader.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios